Advertisement

Agents and Actions

, Volume 30, Issue 1–2, pp 284–286 | Cite as

Dose-response relationship of the H1-histamine antagonist, ebastine, against histamine and methacholine-induced bronchoconstriction in patients with asthma

  • R. Wood-Baker
  • S. T. Holgate
Histamine: Measurement and Clinical Studies

Abstract

In a double blind, randomised, placebo controlled trial in a group of extrinsic asthmatics, we have evaluated the potency and selectivity of ebastine, a new piperidine-type H1-receptor antagonist, against histamine and methacholine-induced bronchoconstriction. The median histamine PC20FEV1 value following placebo was 3.15 mg/ml (0.24–58.84). When compared with placebo, ebastine produced significant protection at 10 mg (median PC20=31.36 mg/ml,p=0.008) and 30 mg (median PC20=42.14 mg/ml,p=0.001) but there appeared to be no significant dose effect. Ebastine also produced a small shift in the methacholine concentration-response curves to the right. We conclude that ebastine is an effective antagonist of histamine-induced bronchoconstriction in the asthmatic airway with evidence of minor blockade of methacholine-induced bronchoconstriction.

Keywords

Placebo Asthma Histamine Placebo Control Trial Methacholine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    H. G. J. Herxheimer,Antihistamines in bronchial asthma. Br. Med. J.2, 901–905 (1949).PubMedGoogle Scholar
  2. [2]
    J. Vincent, R. Liminana, P. A. Meredith and J. L. Reid,The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br. J. clin. Pharmac.26, 497–501 (1988).Google Scholar
  3. [3]
    H. Chai, R. S. Farr, L. A. Froehlich, D. A. Mathison, J. A. McLean and R. R. Rosenthal,Standardization of bronchial inhalation challenge procedures. J. Allergy clin. Immunol.56, 323–327 (1975).PubMedGoogle Scholar
  4. [4]
    P. Rafferty and S. T. Holgate,Terfenadine (Seldane) is a potent and selective histamine H 1 receptor antagonist in asthmatic airways. Am. Rev. respir. Dis.135, 181–184 (1987).PubMedGoogle Scholar
  5. [5]
    S. R. Durham, T. H. Lee, O. Cromwell, R. J. Shaw, T. G. Merrett, J. Merrett, P. Cooper and A. B. Kay,Immunologic studies in allergen-induced late-phase asthmatic reactions. J. Allergy clin. Immunol.74, 49–60 (1984).PubMedGoogle Scholar
  6. [6]
    T. H. Lee, M. J. Brown, L. Nagy, R. Causon, M. J. Walport and A. B. Kay,Exercise-induced release of histamine and neutrophil chemotactic factor in atopic asthmatics. J. Allergy clin. Immunol.70, 73–81 (1982).PubMedGoogle Scholar
  7. [7]
    A. Taytard, D. Beaumont, J. C. Pujet, M. Sapene and P. J. Lewis,Treatment of bronchial asthma with terfenadine; a randomized controlled trial. Br. J. clin. Pharmac.24, 743–746 (1987).Google Scholar

Copyright information

© Birkhäuser Verlag 1990

Authors and Affiliations

  • R. Wood-Baker
    • 1
  • S. T. Holgate
    • 1
  1. 1.Immunopharmacology Group, Medicine 1, Level D, Centre BlockSouthampton General HospitalSouthamptonUK

Personalised recommendations